Proton pump inhibitors and outcome after axicabtagene ciloleucel for the treatment of non-Hodgkin B-cell lymphoma, a retrospective study with the DESCAR-T registry
Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor CAR T-cell (CAR-T), is a major second- or third-line treatment in refractory or early relapsed large B-cell lymphoma (LBCL), primary mediastinal large B-cell lymphoma (PMBL) and follicular lymphoma (FL) [ 1 ]. Although axi-cel induces high complete response rates in relapsed or refractory LBCL, PMBL, and FL, relapse remains the leading cause of treatment failure. Long-term follow-up from ZUMA-1 and ZUMA-5 demonstrates that most progression events occur within the first years after CAR-T infusion [ 2 , 3 ]. Adverse events include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections, associated with increased morbidity and mortality. Understanding the determinants underlying toxicity and relapse is crucial to improve patient outcomes, optimize treatment strategies, and reducing disease burden.
Authors
- Elodie Gat
- Jérôme Paillassa (ORCID: https://orcid.org/0000-0001-5280-018X)
- Aline Schmidt (ORCID: https://orcid.org/0000-0003-0278-7479)
- Roch Houot (ORCID: https://orcid.org/0000-0003-1729-8213)
- Niels Moya
- Martin Eloit
- Eva Desbrousses (ORCID: https://orcid.org/0009-0005-6333-4731)
- Stéphanie Guidez (ORCID: https://orcid.org/0000-0001-8755-5591)
- Nicolas Vallet (ORCID: https://orcid.org/0000-0001-9568-3358)
- Thomas Gastinne (ORCID: https://orcid.org/0000-0003-4704-1187)
- Benoît Tessoulin (ORCID: https://orcid.org/0000-0001-7600-3329)
- Vivien Dupont
- Thierry Lamy de La Chapelle
- Emmanuel Gyan
Institutions
- Université de Tours (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Centre Hospitalier Universitaire de Tours (FR)
- The Lymphoma Academic Research Organisation (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Centre Hospitalier Universitaire d'Angers (FR)
- Centre Hospitalier Universitaire de Rennes (FR)
- Niche, Nutrition, Cancer et métabolisme oxydatif (FR)
Publication Details
- Journal
- Bone Marrow Transplantation
- Published
- 2026-11-06
- DOI
- https://doi.org/10.1038/s41409-026-03076-9
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Centre Hospitalier Universitaire de Rennes